Tina Albertson, MD, Pediatric Hematology & Oncology, Seattle, WA

TinaMAlbertsonMDPhD

Pediatric Hematology & Oncology Seattle, WA

Pediatric Hematologic Oncology

Chief Medical Officer, Drug Development

Dr. Albertson is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Albertson's full profile

Already have an account?

Education & Training

  • University of Washington OtherTraining
  • University of Washington
    University of WashingtonFellowship
  • University of Colorado
    University of ColoradoResidency
  • Stanford University School of Medicine
    Stanford University School of MedicineMedicalSchool

Certifications & Licensure

  • WA State Medical License
    WA State Medical License 2002 - 2020

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cel...
    Tina Albertson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Lisocabtagene Maraleucel (liso-cel) Manufacturing Process Control and Robustness across CD19+ Hematological Malignancies
    Tina Albertson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

  • Sarah Cannon and Lyell Immunopharma Announce Collaboration to Advance Development and Patient Access to T-cell Therapies
    Sarah Cannon and Lyell Immunopharma Announce Collaboration to Advance Development and Patient Access to T-cell TherapiesAugust 27, 2020
  • Mass. General Team Reports First Response of Central Nervous System Tumor to CAR T-cells
    Mass. General Team Reports First Response of Central Nervous System Tumor to CAR T-cellsSeptember 01, 2017